Cue Biopharma, Inc. (CUE)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$16.0M
Cash & Equivalents
$10.9M
Quarterly Burn Rate
4 mo
Est. Cash Runway
$83M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (2)

NCT #TitlePhaseStatusEnrollment
NCT04852328 Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patie... PHASE2 Recruiting 30
NCT06917885 CUE-102 in Recurrent Glioblastoma PHASE1 Recruiting 18

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for CUE.

SEC EDGAR Filings

All SEC filings for Cue Biopharma, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.